Bionano Genomics (BNGO) Set to Post Earnings on Tuesday

Bionano Genomics (NASDAQ:BNGO) is expected to announce its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.45) per share and revenue of $8.44 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

Bionano Genomics (NASDAQ:BNGO) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.03. The business had revenue of ($6.67) million during the quarter, compared to analyst estimates of $7.55 million. Bionano Genomics had a negative return on equity of 78.78% and a negative net margin of 106.58%.

Bionano Genomics Stock Performance

Bionano Genomics stock traded up $0.03 during mid-day trading on Tuesday, hitting $1.19. 57,861 shares of the company’s stock traded hands, compared to its average volume of 446,378. Bionano Genomics has a one year low of $1.00 and a one year high of $2.23. The company has a quick ratio of 1.96, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. The company has a market cap of $16.64 million, a PE ratio of -0.39 and a beta of 1.66. The firm has a 50 day moving average price of $1.37 and a 200 day moving average price of $1.24.

Analysts Set New Price Targets

Several brokerages recently issued reports on BNGO. Wall Street Zen raised Bionano Genomics to a “hold” rating in a research note on Saturday, September 26th. Weiss Ratings upgraded Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $6.00.

About Bionano Genomics

Bionano Genomics, Inc is a life sciences company that develops genomic analysis tools designed to help researchers and clinicians detect large-scale structural variations in DNA. Its technology is intended to complement or extend conventional sequencing and cytogenetic methods by providing information about changes in genome structure, including deletions, duplications, inversions and translocations.

The company’s principal platform is the Saphyr system, an optical genome mapping solution that analyzes ultra-high-molecular-weight DNA.